company background image
PHX logo

PharmX Technologies ASX:PHX Stock Report

Last Price

AU$0.073

Market Cap

AU$43.7m

7D

4.3%

1Y

92.1%

Updated

25 Dec, 2024

Data

Company Financials

PharmX Technologies Limited

ASX:PHX Stock Report

Market Cap: AU$43.7m

PHX Stock Overview

Operates as a technology and software development company in Australia. More details

PHX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Became profitable this year

Risk Analysis

Does not have a meaningful market cap (A$44M)


My Notes

Capture your thoughts, links and company narrative

PharmX Technologies Limited Competitors

Yojee

ASX:YOJ

AU$35.8m

Adacel Technologies

ASX:ADA

AU$34.3m

Xref

ASX:XF1

AU$40.7m

DigitalX

ASX:DCC

AU$49.4m

Price History & Performance

Summary of share price highs, lows and changes for PharmX Technologies
Historical stock prices
Current Share PriceAU$0.073
52 Week HighAU$0.08
52 Week LowAU$0.012
Beta1.17
1 Month Change2.82%
3 Month Change58.70%
1 Year Change92.11%
3 Year Change15.87%
5 Year Change-9.88%
Change since IPO-99.63%

Recent News & Updates

Recent updates

What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

Feb 12
What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

Jul 12
A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

May 11
At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

Nov 12
Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Apr 29
At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 02
Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Dec 13
Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Shareholder Returns

PHXAU SoftwareAU Market
7D4.3%0.8%-1.0%
1Y92.1%64.1%8.5%

Return vs Industry: PHX exceeded the Australian Software industry which returned 64.1% over the past year.

Return vs Market: PHX exceeded the Australian Market which returned 8.5% over the past year.

Price Volatility

Is PHX's price volatile compared to industry and market?
PHX volatility
PHX Average Weekly Movement9.7%
Software Industry Average Movement9.1%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.1%

Stable Share Price: PHX has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: PHX's weekly volatility has decreased from 16% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1950n/aTom Culverpharmx.com.au

PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering gateway; PharmX Marketplace, an online sales and marketing platform; and PharmX Analytics which provides insights for operations of supplier and pharmacy customers. The company was formerly known as Corum Group Limited and changed its name to PharmX Technologies Limited in October 2023.

PharmX Technologies Limited Fundamentals Summary

How do PharmX Technologies's earnings and revenue compare to its market cap?
PHX fundamental statistics
Market capAU$43.69m
Earnings (TTM)AU$95.00k
Revenue (TTM)AU$8.09m

459.9x

P/E Ratio

5.4x

P/S Ratio

Is PHX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHX income statement (TTM)
RevenueAU$8.09m
Cost of RevenueAU$4.13m
Gross ProfitAU$3.96m
Other ExpensesAU$3.87m
EarningsAU$95.00k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.00016
Gross Margin48.97%
Net Profit Margin1.17%
Debt/Equity Ratio0%

How did PHX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 14:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmX Technologies Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caleb WengPAC Partners Securities Pty. Ltd.